Your browser doesn't support javascript.
loading
Dyslipidaemia and statin use in individuals aged 10 to <40 years in the T1D Exchange clinic registry.
Lyons, Sarah K; Boyle, Claire T; DeSalvo, Daniel J; Rickels, Michael R; Wood Heickman, Lauren K; Miller, Kellee M; Foster, Nicole C; Clements, Mark A.
Afiliação
  • Lyons SK; Baylor College of Medicine, Pediatric Diabetes and Endocrinology, Houston, Texas.
  • Boyle CT; Jaeb Center for Health Research, Tampa, Florida.
  • DeSalvo DJ; Baylor College of Medicine, Pediatric Diabetes and Endocrinology, Houston, Texas.
  • Rickels MR; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Wood Heickman LK; University of Virginia School of Medicine, Pediatric Endocrinology and Diabetes, Charlottesville, Virginia.
  • Miller KM; Jaeb Center for Health Research, Tampa, Florida.
  • Foster NC; Jaeb Center for Health Research, Tampa, Florida.
  • Clements MA; Children's Mercy Hospital, Kansas City, Missouri.
Diabetes Obes Metab ; 21(1): 170-172, 2019 01.
Article em En | MEDLINE | ID: mdl-30039636
ABSTRACT
For individuals aged 10 to <40 years with type 1 diabetes and dyslipidaemia, US national guidelines recommend consideration of statin therapy based on age, low-density lipoprotein cholesterol (LDL-C) level and other cardiovascular risk factors. We evaluated dyslipidaemia prevalence, statin therapy use, and associations between not meeting target LDL-C [<100 mg/dL (<5.55 mmol/L)] and other cardiovascular disease (CVD) risk factors in individuals aged 10 to <40 years in the T1D Exchange clinic registry. In 7223 participants, statin use was 2% in 10 to <18 year olds, 4% in 18 to <25 year olds, and 21% in 25 to <40 year olds. Individuals not on statin therapy with LDL-C above target were more likely to have ≥1 additional CVD risk factor(s) than those with LDL-C in the target range for all age groups (all P < 0.01). While most individuals not on statin therapy had LDL-C in the target range, those who did not were more likely to have ≥1 additional CVD risk factor(s), and therefore longitudinal study of lipid levels and statin use is needed to see if treatment of dyslipidaemia to target LDL-C levels may lower the risk of future CVD in individuals aged 10 to <40 years with type 1 diabetes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 1 / Dislipidemias Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Diabetes Mellitus Tipo 1 / Dislipidemias Tipo de estudo: Guideline / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2019 Tipo de documento: Article